Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction
DE Gutstein, R Krishna, D Johns… - Clinical …, 2012 - Wiley Online Library
Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to
raise high‐density lipoprotein cholesterol (HDL‐C) and reduce cardiovascular risk. This …
raise high‐density lipoprotein cholesterol (HDL‐C) and reduce cardiovascular risk. This …
Anacetrapib: a new approach to cardiovascular risk reduction
DE Gutstein, R Krishna, D Johns, HK Surks… - Clin Pharmacol …, 2012 - pace-cme.org
Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
DE Gutstein, R Krishna, D Johns, HK Surks… - Clinical …, 2011 - europepmc.org
Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
[引用][C] Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction
DE Gutstein, R Krishna, D Johns… - Clinical …, 2012 - espace.library.uq.edu.au
Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction
DE Gutstein, R Krishna, D Johns… - Clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This …
[PDF][PDF] anacetrapib, a Novel CETP Inhibitor: Pursuing a New approach to Cardiovascular Risk Reduction
DE Gutstein, R Krishna, D Johns… - CliniCal …, 2012 - researchgate.net
Cholesteryl ester transfer protein (CeTp) inhibition is a promising experimental strategy to
raise high-density lipoprotein cholesterol (hDl-C) and reduce cardiovascular risk. This …
raise high-density lipoprotein cholesterol (hDl-C) and reduce cardiovascular risk. This …
[引用][C] Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
DE Gutstein, R Krishna, D Johns, HK Surks… - Clinical Pharmacology …, 2011 - cir.nii.ac.jp
Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk
Reduction | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
Reduction | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
[引用][C] Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
DE GUTSTEIN, R KRISHNA, D JOHNS… - Clinical …, 2012 - pascal-francis.inist.fr
Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk
Reduction CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
Reduction CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …